TumorTACS In Situ Apoptosis Detection Kit
TumorTACS In Situ Apoptosis Detection Kit Summary
• Unique buffer system produces more consistent labeling.
• Performance tested on tumor samples.
• Includes both Proteinase K and exclusive non-enzymatic Cytonin permeabilization reagent.
• Includes TACS-Nuclease solution for preparing sample-dependent positive controls.
• Helps resolve unique problems encountered when using tissues or cells from tumors.
Why Use TumorTACS In Situ Apoptosis Detection Kit?
The labeling of tumor-containing specimens can be problematic due to the high levels of necrosis in these tissues. During necrosis, cessation of homeostasis, cell swelling, and nuclear membrane rupture generates highly degraded DNA that can interfere with interpretation of data.
- In situ detection of apoptosis in fixed frozen, paraffin embedded, or plastic embedded cells and tissues.
- Assists in the identification of apoptotic morphologies.
• Proteinase K
• DAB Enhancer
• TACS-Nuclease Buffer
• Methyl Green 1%
• TACS 2 TdT Labeling Buffer
• TACS 2 TdT Stop Buffer
• TACS 2 TdT dNTP
• TdT Enzyme
• 50x Manganese Cation
For research use only. Not for diagnositic use.
Apoptotic Cells within a Mouse Mammary Tumor Identified using the TumorTACS In Situ Apoptosis Detection Kit. Mammary tumor tissue was fixed in 4% paraformaldehyde overnight and paraffin-embedded. Five micron sections were prepared and placed onto glass microscope slides. The sample was processed following the TumorTACS Kit protocol (Catalog # 4815-30-K). Brown stained nuclei indicate apoptotic cells.
Citations for TumorTACS In Situ Apoptosis Detection Kit
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 10
Filter your results:
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2?+?murine breast cancer model
Authors: F Andreata, A Bonizzi, M Sevieri, M Truffi, M Monieri, L Sitia, F Silva, L Sorrentino, R Allevi, P Zerbi, B Marchini, E Longhi, R Ottria, S Casati, R Vanna, C Morasso, M Bellini, D Prosperi, F Corsi, S Mazzucchel
Sci Rep, 2020;10(1):11425. 2020
Tussilagone Reduces Tumorigenesis by Diminishing Inflammation in Experimental Colitis-Associated Colon Cancer
Authors: SH Nam, JK Kim
Biomedicines, 2020;8(4):. 2020
Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells
Authors: Y Tatsumi, M Miyake, K Shimada, T Fujii, S Hori, Y Morizawa, Y Nakai, S Anai, N Tanaka, N Konishi, K Fujimoto
Int J Mol Sci, 2020;21(11):. 2020
Cyclopamine tartrate, a modulator of hedgehog signaling and mitochondrial respiration, effectively arrests lung tumor growth and progression
Authors: SP Kalainayak, P Ghosh, S Dey, KE Fitzgerald, S Sohoni, PC Konduri, M Garrossian, L Liu, L Zhang
Sci Rep, 2019;9(1):1405. 2019
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
Authors: X Liu, J Hu, X Song, K Utpatel, Y Zhang, P Wang, X Lu, J Zhang, M Xu, T Su, L Che, J Wang, M Evert, DF Calvisi, X Chen
Cancers (Basel), 2019;11(7):. 2019
IPMK Mediates Activation of ULK Signaling and Transcriptional Regulation of Autophagy Linked to Liver Inflammation and Regeneration
Authors: P Guha, R Tyagi, S Chowdhury, L Reilly, C Fu, R Xu, AC Resnick, SH Snyder
Cell Rep, 2019;26(10):2692-2703.e7. 2019
Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats
Authors: ZE Plyler, SE Birket, BD Schultz, JS Hong, SM Rowe, CF Petty, MR Crowley, DK Crossman, TR Schoeb, EJ Sorscher
Mech. Dev., 2019;155(0):15-26. 2019
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Authors: Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark R, Kupper T, Palmer K, Coll M, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D
Blood, 2015;126(3):354-62. 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
Authors: Jain S, Jirau-Serrano X, Zullo K, Scotto L, Palermo C, Sastra S, Olive K, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual J, Deng C, Karan C, Realubit R, Bates S, O'Connor O
Clin Cancer Res, 2015;21(9):2096-106. 2015
TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
Authors: Zhu K, Fang W, Chen Y, Lin S, Chen X
Oncol Rep, 2014;32(3):1234-42. 2014
Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways.
Authors: Lin, Jiumao, Shen, Aling, Chen, Hongwei, Liao, Jun, Xu, Teng, Liu, Liya, Lin, Jing, Peng, Jun
BMC Cancer, 2014;14(0):729. 2014
Distinct phospholipase C-beta isozymes mediate lysophosphatidic acid receptor 1 effects on intestinal epithelial homeostasis and wound closure.
Authors: Lee S, Leoni G, Neumann P, Chun J, Nusrat A, Yun C
Mol Cell Biol, 2013;33(10):2016-28. 2013
Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production.
Authors: Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM
PLoS ONE, 2011;6(8):e23317. 2011
Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.
Authors: Hua Y, White-Gilbertson S, Kellner J, Rachidi S, Usmani S, Chiosis G, Depinho R, Li Z, Liu B
Clin Cancer Res, 0;19(22):6242-51. 0
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Authors: Barone T, Burkhart C, Safina A, Haderski G, Gurova K, Purmal A, Gudkov A, Plunkett R
Neuro Oncol, 0;19(2):186-196. 0
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection.
Authors: Martin F, McKie P, Cataliotti A, Sangaralingham S, Korinek J, Huntley B, Oehler E, Harders G, Ichiki T, Mangiafico S, Nath K, Redfield M, Chen H, Burnett J
Am J Physiol Regul Integr Comp Physiol, 0;302(2):R292-9. 0
Bifurcation of axons from cranial sensory neurons is disabled in the absence of Npr2-induced cGMP signaling.
Authors: Ter-Avetisyan G, Rathjen F, Schmidt H
J Neurosci, 0;34(3):737-47. 0
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.
Authors: Liu Y, Sun S, Owonikoko T, Sica G, Curran W, Khuri F, Deng X
Mol Cancer Ther, 0;11(1):45-56. 0
No product specific FAQs exist for this product, however you mayView all FAQs
Reviews for TumorTACS In Situ Apoptosis Detection Kit
There are currently no reviews for this product. Be the first to review TumorTACS In Situ Apoptosis Detection Kit and earn rewards!
Have you used TumorTACS In Situ Apoptosis Detection Kit?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image